I describe a simple and intuitive method for finding sample size for clinical trials in primary breast cancer based on neoadjuvant trial results and using the FDA's patient-level meta-analysis. Then I explain a problem with this method and how the problem can be remedied. Clin Cancer Res; 22(1); 3–5. ©2015 AACR.
See related article by Hatzis et al., p. 26
from Cancer via ola Kala on Inoreader http://ift.tt/1Jpa3IG
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου